Permanent URL of this page: www.oecd.org/sti/biotechnology/genomics
Work in the area of genetics and genomics undertaken by the OECD:
The OECD Working Party on Biotechnology has developed guidelines on human biobanks and genetic research databases (HBGRDs) through an expert group of member countries. The resulting recommendation, adopted by the OECD Council in October 2009, is intended to assist both OECD and non-OECD governments in the development of policies applicable to HBGRDs and to provide guidance for private and public sector HBGRDs.
In May 2007, OECD member countries adopted the Guidelines for Quality Assurance in Molecular Genetic Testing. The guidelines offer principles and best practices for the quality assurance of molecular genetic testing offered in a clinical context.
In February 2006, OECD member countries adopted the Guidelines for the Licensing of Genetic Inventions. The guidelines offer principles and best practices for the licensing of intellectual property rights that relate to genetic inventions used for the purpose of human health care.
Published in November 2009, the book Pharmacogenetics: Opportunities and Challenges for Health Innovation and Care examines the challenges facing pharmacogenetics across the health innovation cycle and into the clinic, and reviews the impact to date of pharmacogenetics on both pharmaceutical R&D and clinical care.
Biomarkers and Targeted Therapies
Scientific advances in biotechnology are ushering in a new era of medicine: targeted therapies and personalized medicine are coming of age. Traditional medicine manages a disease through standard treatments, without taking account of existing variability between individuals or groups of population. A report on this activity will be posted in Spring 2011.
For more information, please contact: stibiotech
Last updated : 29 November 2010